


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.89%
+0.30%
-1.43%
+0.96%
+15.95%
ORGO
Organogenesis Holdin
$4.64
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
ORGO Price Performance
$4.74 (-2.11%)
$4.13 (+12.35%)
$4.89 (-5.11%)
$3.53 (+31.44%)
ORGO has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

ORGO overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
ORGO Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ORGO Street Sentiment is bullish and have negative views on the near-term outlook
Average key support and resistance price levels
What is ORGO current stock price?
What are ORGO stock strengths?
What is ORGO Risk Level?
What is ORGO market cap and volume?
What is ORGO current Stock IQ?
Should I buy ORGO stock right now?
Is ORGO a Strong Buy right now?
What does a 'Strong Buy' rating mean for ORGO?
What does a 'Strong Sell' rating mean for ORGO?
What factors influence ORGO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.89%
+0.30%
-1.43%
+0.96%
+15.95%
ORGO
Organogenesis Holdin
Current Price
$4.64
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

ORGO Price Performance
$4.74 (-2.11%)
$4.13 (+12.35%)
$4.89 (-5.11%)
$3.53 (+31.44%)
ORGO Analysts Opinion
ORGO Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
ORGO Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ORGO Street Sentiment is bullish and have negative views on the near-term outlook
ORGO has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
ORGO Stock IQ
ORGO Latest Analysis
Organogenesis drops as Medicare to pull skin substitute LCDs (update).
Fri Dec 26, 2025
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision.
Fri Dec 26, 2025
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis . (RTTNews) - Organogenesis Holdings Inc. (ORGO) a regenerative medicine company announced that it has initiated the submission of a Biologics License Application or BLA to the US Food and Drug Administration or FDA for its lead amniotic suspension allograft ReNu for the managem
Wed Dec 24, 2025
Organogenesis starts rolling submission for ReNu allograft for knee arthritis.
Tue Dec 23, 2025
BTIG Reiterates Organogenesis Holdings (ORGO) Buy Recommendation. Fintel reports that on December 15 2025 BTIG reiterated coverage of Organogenesis Holdings (NasdaqCM:ORGO) with a Buy recommendation. Analyst Price Forecast Suggests 79.50% Upside
Tue Dec 16, 2025
Organogenesis To File Rolling BLA For ReNu Following FDA Meeting . (RTTNews) - Organogenesis Holdings Inc. (ORGO) announced the successful completion of a planned Type-B meeting with the United States FDA confirming that the company may initiate a rolling Biologics License Application for ReNu in knee osteoarthritis pain.
Tue Dec 16, 2025
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain. Clinical Development Program Appropriate for Rolling BLA
Mon Dec 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ORGO Stock trends
ORGO Stock performance
ORGO Stock analysis
ORGO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.